Ybrain Expands Distribution Network for Electronic Migraine Drug 'Dupang'

Ybrain's Electronic Migraine Drug 'Dupang'

[Asia Economy Reporter Chunhee Lee] Electronic medicine platform company Ybrain is expanding the distribution network of its migraine relief medical device 'Dupang'.

Ybrain announced on the 20th that it has signed a contract to place Dupang in over 100 pharmacies nationwide through the nationwide pharmacy chain Daypharm. This contract is the largest distribution agreement since the first pharmacy placement contract for Dupang in March.

Daypharm is a pharmacy distribution chain with a network of about 200 pharmacies nationwide. Through this contract, Ybrain plans to initially place Dupang in 100 Daypharm chain pharmacies and then continue to increase the number of pharmacies carrying the product. Ybrain plans to continuously expand Dupang's distribution to pharmacies nationwide, starting with the contract with Daypharm.

Dupang is a migraine relief medical device developed domestically for the first time and approved by the Ministry of Food and Drug Safety. It delivers transcutaneous electrical nerve stimulation (TENS) to the trigeminal nerve area on the forehead that causes migraines, stabilizing the overactive nerves to relieve migraines, and with consistent use, reduces the frequency of migraine occurrences.

Lee Gi-won, CEO of Ybrain, said, “We plan to continuously expand pharmacy placements to increase consumer accessibility to Dupang, a general electronic medicine that can be purchased directly at pharmacies,” adding, “We hope that consumers who have resistance to medication can actively manage migraines through Dupang and recover a healthy daily life.”

This content was produced with the assistance of AI translation services.